Loading the section
Closing prices for 09 October 2026
Next earnings report: 03 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Madrigal Pharmaceuticals, Inc. trades on Nasdaq under the ticker MDGL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks MDGL has traded between 393.61 $ and 615.00 $. As of 09 October 2026 the price stood 35.30 % of the way from the 52-week low to the high.
Over one year MDGL shares rose 7.96 %; over six months they fell 9.21 %. Volatility over 90 days is 39.78 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 9.8, above the sector median of 3.9. Price to book is 20.5, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 477.48 | 483.64 | 470.53 | 471.75 | 312,984 |
| 08 October 2026 | 486.37 | 492.33 | 466.06 | 476.91 | 374,400 |
| 07 October 2026 | 492.69 | 502.34 | 486.77 | 487.72 | 256,200 |
| 06 October 2026 | 497.08 | 504.06 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Madrigal brought out the first approved drug for fatty liver disease — a condition with no treatment for decades.
The disease is far more widespread than is commonly thought: it develops alongside excess weight and diabetes and progresses without symptoms for years until it causes cirrhosis. Until now a doctor could only recommend weight loss, and many developers failed here.
Approval of the first drug opened the market, but its size will be determined not by science but by how many patients are identified and reimbursed by insurers: diagnosis requires a specialised liver assessment that is not available everywhere. The company is at the launch stage and unprofitable. Risks: adoption pace, competition and the need for capital.
Address:200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428, US
Madrigal Pharmaceuticals, Inc. reported revenue of 1.1B $ and a net loss of 309M $ over the last four quarters. Net margin is −27.32 %. Revenue changed by +256.82 % year over year. Earnings per share are −12.78 $. Market capitalisation is 11.1B $.
MDGL has a return on equity of −56.94 %, below the sector median of −41.68 %. Return on assets is −25.21 %, above the sector median of −32.11 %. Operating margin is −27.68 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 478.71 |
| 496.45 |
| 330,300 |
| 05 October 2026 | 501.89 | 505.00 | 491.25 | 493.62 | 246,500 |
| 02 October 2026 | 505.00 | 505.00 | 491.05 | 499.40 | 289,200 |
| 01 October 2026 | 502.28 | 510.00 | 497.73 | 499.71 | 204,600 |
| 30 September 2026 | 513.10 | 515.00 | 501.81 | 503.96 | 262,500 |
| 29 September 2026 | 513.73 | 518.67 | 505.32 | 509.44 | 214,400 |
| 28 September 2026 | 515.10 | 525.00 | 502.68 | 517.04 | 333,700 |
| 25 September 2026 | 513.75 | 523.96 | 511.31 | 516.56 | 153,400 |
| 24 September 2026 | 513.65 | 521.77 | 510.57 | 513.21 | 219,300 |
| 23 September 2026 | 523.00 | 526.00 | 502.63 | 513.02 | 315,900 |
| 22 September 2026 | 525.77 | 528.42 | 516.62 | 518.83 | 266,100 |
| 21 September 2026 | 536.04 | 536.04 | 515.98 | 521.96 | 186,100 |
| 18 September 2026 | 535.08 | 537.73 | 526.65 | 531.52 | 330,600 |
| 17 September 2026 | 534.69 | 539.29 | 526.26 | 534.40 | 153,300 |
| 16 September 2026 | 523.00 | 529.93 | 517.45 | 529.09 | 298,500 |
| 15 September 2026 | 539.25 | 539.71 | 513.36 | 523.26 | 259,400 |
| 14 September 2026 | 540.00 | 541.35 | 527.97 | 540.06 | 156,500 |